Trial · NCT01765764
Bimatoprost for the Treatment of Eyebrow Hypotrichosis
NCT01765764, Phase 3, Completed, Allergan; results first posted 2015-01-26
3 sourcestrials-2026-11-12-0.5.0
Download JSON
Cite this record
ConductScience Library. Bimatoprost for the Treatment of Eyebrow Hypotrichosis. Trials, record NCT01765764. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT01765764
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Bimatoprost for the Treatment of Eyebrow Hypotrichosis
- NCT number
- NCT01765764
- Status
- Completed
- Phases
- Phase 3
- Enrollment
- 357 participants, actual
- Lead sponsor
- Allergan
- Conditions
- Eyebrow Hypotrichosis
- Interventions
- bimatoprost solution, Vehicle to bimatoprost solution
- First posted
- 2013-01-10
- Last updated
- 2019-04-23
- Results first posted
- 2015-01-26
Source ClinicalTrials.gov
Registered outcomes4
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Percentage of Participants With at Least a 1-Grade Increase (Improvement) in the 4-Point Global Eyebrow Assessment (GEBA) Scale | Baseline, Month 7 | The physician evaluated eyebrow fullness using the 4-point GEBA Scale where: 1=very sparse, 2=sparse, 3=full and 4=very full. The percentage of participants with at least a 1-grade increase from Baseline is reported. |
| Secondary | Change From Baseline in Eyebrow Fullness as Measured Using Digital Monitoring System Image Analysis (DMSIA) | Baseline, Month 7 | Photographs were taken of the eyebrows. Eyebrow fullness was measured by DMSIA for both eyes and averaged. Eyebrow fullness was reported in millimeters squared (mm\^2). A positive change from Baseline indicated fuller eyebrows (improvement). |
| Secondary | Change From Baseline in Eyebrow Darkness as Measured Using DMSIA | Baseline, Month 7 | Photographs were taken of the eyebrows. Eyebrow darkness (intensity) was measured by DMSIA for both eyes and averaged. Eyebrow darkness was reported in intensity units. A negative change from Baseline indicated darker eyebrows (improvement). |
| Secondary | Percentage of Participants With 'Very Satisfied' or 'Mostly Satisfied' in Eyebrow Satisfaction Scale (ESS) Item #6 | Month 7 | ESS Item #6 measured the participant's satisfaction with eyebrow treatment: "Overall, how satisfied are you with the way the eyebrow treatment makes your eyebrows look right now?" using a 5-point scale where: 1=very satisfied, 2=mostly satisfied, 3=neither dissatisfied nor satisfied, 4=mostly dissatisfied and 5=very dissatisfied. The percentage of participants 'very satisfied' or 'mostly satisfied' is reported. |
Source ClinicalTrials.gov
Outcomes4
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
| Type | Outcome | Time frame | Population | Units | Measured as |
|---|---|---|---|---|---|
| PRIMARY | Percentage of Participants With at Least a 1-Grade Increase (Improvement) in the 4-Point Global Eyebrow Assessment (GEBA) Scale | Baseline, Month 7 | Intent-to-treat population included all randomized participants. | percentage of participants | NUMBER |
| SECONDARY | Change From Baseline in Eyebrow Fullness as Measured Using Digital Monitoring System Image Analysis (DMSIA) | Baseline, Month 7 | Participants from the Intent-to-treat population, all randomized participants, with data available for analysis. | mm^2 | MEAN |
| SECONDARY | Change From Baseline in Eyebrow Darkness as Measured Using DMSIA | Baseline, Month 7 | Participants from the Intent-to-treat population, all randomized participants, with data available for analysis. | intensity units | MEAN |
| SECONDARY | Percentage of Participants With 'Very Satisfied' or 'Mostly Satisfied' in Eyebrow Satisfaction Scale (ESS) Item #6 | Month 7 | Intent-to-treat population included all randomized participants. | percentage of participants | NUMBER |
Source ClinicalTrials.gov
Results by group18
Each measurement the trial posted, group by group, in the words and numbers it posted.
| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Percentage of Participants With at Least a 1-Grade Increase (Improvement) in the 4-Point Global Eyebrow Assessment (GEBA) Scale | Bimatoprost Solution BID | 83.9 | percentage of participants | ||
| Percentage of Participants With at Least a 1-Grade Increase (Improvement) in the 4-Point Global Eyebrow Assessment (GEBA) Scale | Bimatoprost Solution QD | 77.1 | percentage of participants | ||
| Percentage of Participants With at Least a 1-Grade Increase (Improvement) in the 4-Point Global Eyebrow Assessment (GEBA) Scale | Vehicle to Bimatoprost Solution BID | 43.0 | percentage of participants | ||
| Change From Baseline in Eyebrow Fullness as Measured Using Digital Monitoring System Image Analysis (DMSIA) | Bimatoprost Solution BID | Baseline | 101.08 | Standard Deviation 47.252 | mm^2 |
| Change From Baseline in Eyebrow Fullness as Measured Using Digital Monitoring System Image Analysis (DMSIA) | Bimatoprost Solution QD | Baseline | 97.80 | Standard Deviation 41.525 | mm^2 |
| Change From Baseline in Eyebrow Fullness as Measured Using Digital Monitoring System Image Analysis (DMSIA) | Vehicle to Bimatoprost Solution BID | Baseline | 98.17 | Standard Deviation 49.657 | mm^2 |
| Change From Baseline in Eyebrow Fullness as Measured Using Digital Monitoring System Image Analysis (DMSIA) | Bimatoprost Solution BID | Change from Baseline at Month 7 | 34.51 | Standard Deviation 35.940 | mm^2 |
| Change From Baseline in Eyebrow Fullness as Measured Using Digital Monitoring System Image Analysis (DMSIA) | Bimatoprost Solution QD | Change from Baseline at Month 7 | 30.96 | Standard Deviation 33.638 | mm^2 |
| Change From Baseline in Eyebrow Fullness as Measured Using Digital Monitoring System Image Analysis (DMSIA) | Vehicle to Bimatoprost Solution BID | Change from Baseline at Month 7 | 6.42 | Standard Deviation 26.870 | mm^2 |
| Change From Baseline in Eyebrow Darkness as Measured Using DMSIA | Bimatoprost Solution BID | Baseline | 53.90 | Standard Deviation 6.314 | intensity units |
1 to 10 of 18Source ClinicalTrials.gov
See all 18 results by groupParticipant flow18
How many started, completed or left each group, period by period.
| Period | Milestone | Group | Participants | Units counted |
|---|---|---|---|---|
| Treatment Period | STARTED | Bimatoprost Solution BID | 118 | |
| Treatment Period | STARTED | Bimatoprost Solution QD | 118 | |
| Treatment Period | STARTED | Vehicle to Bimatoprost Solution BID | 121 | |
| Treatment Period | COMPLETED | Bimatoprost Solution BID | 115 | |
| Treatment Period | COMPLETED | Bimatoprost Solution QD | 109 | |
| Treatment Period | COMPLETED | Vehicle to Bimatoprost Solution BID | 115 | |
| Treatment Period | NOT COMPLETED | Bimatoprost Solution BID | 3 | |
| Treatment Period | NOT COMPLETED | Bimatoprost Solution QD | 9 | |
| Treatment Period | NOT COMPLETED | Vehicle to Bimatoprost Solution BID | 6 | |
| Post-treatment Period | STARTED | Bimatoprost Solution BID | 114 |
1 to 10 of 18Source ClinicalTrials.gov
See all 18 participant flowAdverse events18
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
| Type | Event | Organ system | Group | Affected | At risk | Events |
|---|---|---|---|---|---|---|
| other | Upper respiratory tract infection | Infections and infestations | Bimatoprost Solution BID | 6 | 118 | |
| other | Upper respiratory tract infection | Infections and infestations | Bimatoprost Solution QD | 5 | 118 | |
| other | Upper respiratory tract infection | Infections and infestations | Vehicle to Bimatoprost Solution BID | 7 | 121 | |
| serious | Basal cell carcinoma | Neoplasms benign, malignant and unspecified (incl cysts and polyps) | Bimatoprost Solution BID | 1 | 118 | |
| serious | Basal cell carcinoma | Neoplasms benign, malignant and unspecified (incl cysts and polyps) | Bimatoprost Solution QD | 0 | 118 | |
| serious | Basal cell carcinoma | Neoplasms benign, malignant and unspecified (incl cysts and polyps) | Vehicle to Bimatoprost Solution BID | 2 | 121 | |
| serious | Breast cancer | Neoplasms benign, malignant and unspecified (incl cysts and polyps) | Bimatoprost Solution BID | 1 | 118 | |
| serious | Breast cancer | Neoplasms benign, malignant and unspecified (incl cysts and polyps) | Bimatoprost Solution QD | 0 | 118 | |
| serious | Breast cancer | Neoplasms benign, malignant and unspecified (incl cysts and polyps) | Vehicle to Bimatoprost Solution BID | 0 | 121 | |
| serious | Gastrointestinal disorder | Gastrointestinal disorders | Bimatoprost Solution BID | 0 | 118 |
1 to 10 of 18Source ClinicalTrials.gov
See all 18 adverse eventsAdverse event totals9
The totals the trial posted for each group.
| Total | Group | Affected | At risk |
|---|---|---|---|
| Total, all-cause mortality | Bimatoprost Solution BID | ||
| Total, all-cause mortality | Bimatoprost Solution QD | ||
| Total, all-cause mortality | Vehicle to Bimatoprost Solution BID | ||
| Total, other adverse events | Bimatoprost Solution BID | 6 | 118 |
| Total, other adverse events | Bimatoprost Solution QD | 5 | 118 |
| Total, other adverse events | Vehicle to Bimatoprost Solution BID | 7 | 121 |
| Total, serious adverse events | Bimatoprost Solution BID | 2 | 118 |
| Total, serious adverse events | Bimatoprost Solution QD | 0 | 118 |
| Total, serious adverse events | Vehicle to Bimatoprost Solution BID | 5 | 121 |
Source ClinicalTrials.gov
Papers1
The papers the trial lists on ClinicalTrials.gov.
| PMID | Listed as |
|---|---|
| 27124878 | BACKGROUND |
Source PubMed
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT01765764
GET https://conductscience.org/api/trials/v1/NCT01765764/registered